DMR News

Advancing Digital Conversations

Singapore biotech startup secures $4 million in seed financing from Elev8 and Seeds Capital

ByYasmeeta Oon

Apr 18, 2024
visually represent the essence and excitement of the biotech industry's innovation and growth.

Singapore biotech startup secures $4 million in seed financing from Elev8 and Seeds Capital

In a significant boost to the future of precision healthcare, Auristone, a groundbreaking biotechnology startup, has successfully closed a US$4 million seed funding round. This financial injection marks a pivotal moment in the company’s journey towards revolutionizing the way genetic diseases, particularly cancer, are treated, thanks to its innovative use of epigenomics.

The funding round was spearheaded by Elev8, a venture capital firm known for its keen investment in disruptive healthcare technologies. Elev8’s participation was notably accompanied by Seeds Capital, the investment arm of Enterprise Singapore, and Genedant, an existing investor who has reaffirmed their confidence in Auristone’s mission and technology.

InvestorRoleContribution
Elev8Lead InvestorStrategic guidance and major funding contribution
Seeds CapitalCo-InvestorSupport for market expansion and adoption in Asia
GenedantExisting InvestorOngoing financial and strategic support reflecting continued confidence

Aditya Mathur, Managing Director at Elev8, expressed his enthusiasm for Auristone’s work, stating, “The human epigenome is the next frontier for unlocking precision healthcare.” He highlighted Auristone’s unique position in the field, thanks to its proprietary technology that profiles molecules and predicts their medical interactions using epigenomics biomarkers. This capability, according to Mathur, sets Auristone apart as a leader in the exploration and application of epigenomic science for healthcare advancement.

Auristone’s focus on epigenomics—the study of the chemical compounds and proteins that tell the genome what to do—positions it at the cutting edge of genetic research and treatment. The startup’s flagship product, Epi-Call, epitomizes this innovative edge. Epi-Call is a molecular profiling technology designed to predict an individual’s likelihood of responding to various cancer treatment options, thereby personalizing and enhancing the efficacy of healthcare.

  • Personalized Medicine: Epi-Call represents a leap towards truly personalized medicine, where treatments are tailored to the genetic makeup of the individual, improving outcomes and minimizing side effects.
  • Predictive Analytics: Utilizes advanced algorithms to predict patient responses to different treatments, enabling doctors to make more informed decisions.
  • Epigenomic Profiling: Goes beyond traditional genetic testing to provide a deeper understanding of how genes interact with their environment, opening new avenues for treatment.

The seed funding will be primarily directed towards expanding clinical collaborations and increasing the market presence of Epi-Call. Auristone’s strategy focuses on not just improving the technology behind Epi-Call but also ensuring its adoption by healthcare providers and acceptance by patients.

Seeds Capital’s General Manager, Tan Kaixin, echoed the sentiment of strong support for Auristone’s vision and technology. “Seeds Capital looks forward to supporting Auristone as it scales into new markets such as South Korea, Japan, and beyond,” said Tan. He highlighted the potential for epigenomics to transform genomic testing and, by extension, to create more personalized, effective healthcare solutions.

The implications of Auristone’s work and the successful funding round extend far beyond the immediate advancements in cancer treatment. By leading the charge in epigenomic research and its applications, Auristone is paving the way for a future where healthcare is not only reactive but predictive and personalized. This paradigm shift promises to change the landscape of medicine, making diseases like cancer not just treatable but potentially preventable.

  • Market Expansion: With the backing of its investors, Auristone plans to enter new markets, focusing on Asia, with a special emphasis on South Korea and Japan.
  • Clinical Collaborations: Strengthening partnerships with healthcare institutions to validate Epi-Call’s efficacy and integrate it into standard care practices.
  • Research and Development: Continued investment in R&D to further refine Epi-Call and explore new applications of epigenomics in healthcare.

The journey of Auristone, from a promising startup to a potential leader in precision healthcare, reflects the broader trends in biotechnology and medicine. As the world grapples with complex health challenges, the work of companies like Auristone offers hope for a future where each patient’s treatment is as unique as their DNA. With the support of visionary investors and a commitment to innovation, Auristone stands on the cusp of making that future a reality.

The successful seed funding round for Auristone is more than just a financial milestone. It’s a testament to the faith in the transformative power of epigenomics and a beacon for the future of personalized healthcare. As Auristone embarks on this exciting phase of growth and discovery, it carries the potential to redefine how we understand, treat, and ultimately prevent genetic diseases.


Related News:


Featured Image courtesy of DALL-E by ChatGPT

Yasmeeta Oon

Just a girl trying to break into the world of journalism, constantly on the hunt for the next big story to share.

Leave a Reply

Your email address will not be published. Required fields are marked *